AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company dedicated to the research and development of therapeutics for various cancers, viral diseases, and immune-deficiency disorders. Headquartered in Ocala, Florida, the company's mission is to advance immunology and harness the body's healing capabilities, particularly in the treatment of lethal cancers and severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
The company's flagship product is Ampligen® (rintatolimod), a first-in-class investigational drug that functions as a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator. Ampligen is currently being evaluated in clinical studies for a range of debilitating and life-threatening conditions, including various cancers (such as pancreatic, ovarian, and renal cell carcinoma), viral diseases (including COVID-19, Hepatitis B, and HIV), and immune disorders like ME/CFS and post-COVID conditions. While Ampligen is approved for commercial sale in Argentina for severe ME/CFS, AIM ImmunoTech also produces Alferon N Injection® (Interferon alfa), which is FDA-approved in the United States for the intralesional treatment of refractory or recurring external genital warts.
Under the leadership of CEO Thomas K. Equels, who has served since February 2016, AIM ImmunoTech is actively progressing its clinical programs. The company recently announced plans for a Phase 3 clinical trial of Ampligen in late-stage pancreatic cancer, building on promising results from its ongoing Phase 2 DURIPANC study. In recent news, AIM ImmunoTech secured patent approvals in Japan and the Netherlands for Ampligen's use in combination with checkpoint inhibitors for cancer treatment and for treating post-COVID fatigue, respectively. The company also completed a rights offering in March 2026. Despite facing notices of non-compliance and delisting from NYSE American due to low stock price, the company plans to appeal these determinations, emphasizing its focus on advancing immuno-pharma therapeutics for unmet medical needs.
Latest updates